Intellectual property and trade

#HandsOffOurMeds

Incredible India truck in front of Whitehouse Photograph by Ken Cedeno
Learn more
#HandsOffOurMeds Intellectual property and trade generic medicines

Don't shut down the pharmacy of the developing world

0

Take action now!

Urge Indian Prime Minister Modi to protect India’s production of lifesaving affordable generic medicines. 👇

MSF to @PMOIndia: Protect the pharmacy of the developing world! http://ow.ly/NU10k #HandsOffOurMeds


On
Back to top ↑

Médecins Sans Frontières (MSF) relies heavily on generic medicines made in India to carry out its medical work in more than 60 countries. But the ‘pharmacy of the developing world’ is under attack from the US, the EU, Japan and others who are protecting multinational pharmaceutical profits over peoples’ lives.

Don't shut down the pharmacy of the developing world!

Millions of people around the world rely on affordable medicines made in India to stay alive.

bottom-center
Off
Off
Off
Center hero text
Left

MSF statement on WHA72: Access to medicines and vaccines, Document A72/17 - agenda item 11.7

72nd WHO World Health Assembly – May 2019
Médecins Sans Frontières (MSF) statement on agenda item 11.7: Access to medicines and vaccines, Document A72/17

Speaker: Gaelle Krikorian

MSF welcomes the road map and the holistic approach it provides for WHO’s work on access to medicines. We are here to ask Member States to take a specific step to deliver on the road map’s potential.

Exorbitant medicine prices limit MSF’s ability to provide the best possible treatment for people in our care. The same holds true for governments represented here today. This week, Member States are negotiating an important resolution on medicines transparency – covering four areas where full transparency is urgently needed: research and development (R&D) costs, clinical trial results, medicines patents, and the real prices of medicines.

This resolution could help save lives by setting strong norms and standards to help correct the unacceptable power imbalance that exists between those who need and purchase medicines – and those who produce and sell them.

Pharmaceutical corporations do not set medicine prices with the objective of ensuring access for all people in need. They set them in order to maximise profit, which leads to rationing of medicines when patients and health systems cannot afford the prices they charge. When governments sign confidentiality agreements on prices, they give companies the upper hand in price negotiations. But countries do not have to consent to being blindfolded. There are no legal barriers that mandate this damaging secrecy.

Transparency can help level the playing field and give governments the information they need to negotiate fairly and responsibly for people and their health. We ask Member States to require transparency on the prices countries pay for medicines, the mark-ups companies charge, and companies’ production costs. And governments need to know who pays what for R&D – how much investment is really covered by companies, and how much is underwritten by taxpayers and non-profit groups.

MSF urges Member States to adopt a bold and clear resolution to set strong standards that mandate transparency on medicine prices and R&D costs.

World Health AssemblyWorld Health Organization Intellectual property and tradeResearch and development Statement
Photograph by UN Photo/Eskinder Debebe Photograph by UN Photo/Eskinder Debebe
Off
0
center

A Matter of Life & Death: The Role of Patents in Access to Essential Medicines

MSF briefing for the 4th WTO Ministerial Conference in Doha, Qatar. Includes articles on how generic competition brings down drug prices, TRIPS safeguards in use in developed countries, and why donations won’t solve the access crisis, among others. Ends with recommendations to the WTO members to support a pro-public health interpretation of the TRIPS Agreement.

Read more here.

Intellectual property and trade Issue brief Doha Declaration

The Role of Patents in Access to Essential Medicines

Off
0
center

Opposing patent application for bedaquiline formulation in India

In an effort to make lifesaving drugs accessible to all people, civil society organisations around the world have worked tirelessly to remove patent barriers on drugs for the treatment of cancer, HIV and hepatitis C. In India, the largest manufacturer of affordable drugs for the developing world, the struggle to scale up access to medicines for drug-resistant tuberculosis (DR-TB) is now at a decisive stage. Médecins Sans Frontières (MSF) and civil society organisations in the country are supporting a patent challenge filed by two TB survivors in order to prevent pharmaceutical corporation Johnson & Johnson (J&J) from extending its monopoly on the core DR-TB drug bedaquiline.

drug-resistant TBtuberculosis bedaquiline India Intellectual property and tradeTuberculosis Technical brief patent opposition
XDR-TB patient Nischaya, at home the Ambedkar Nagar area of Mumbai, with her TB medication. Photography by Atul Loke
Off
0
top-center
Subscribe to Intellectual property and trade